双碳青霉烯方案治疗耐碳青霉烯类肠杆科细菌研究进展

叶超; 王朝晖; 胡英; 宋露萍; 周维; 廖玲珑; 王春江<sup>*</sup>

引用本文:	叶超,王朝晖,胡英,宋露萍,周维,廖玲珑,王春江.双碳青霉烯方案治疗耐碳青霉烯类肠杆科细菌研究进展[J].中国现代应用药学,2020,37(20):2555-2560.
	YE Chao,WANG Zhaohui,HU Ying,SONG Luping,ZHOU Wei,LIAO Linglong,WANG Chunjiang.Advances in the Treatment of Carbapenem-resistant Enterobacteria by the Double Carbapenem Regimen[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(20):2555-2560.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 1493次下载 974次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
双碳青霉烯方案治疗耐碳青霉烯类肠杆科细菌研究进展
叶超¹, 王朝晖¹, 胡英¹, 宋露萍¹, 周维¹, 廖玲珑², 王春江³
1.湖南中医药大学附属宁乡市人民医院药学部, 长沙 410600;2.广州市增城区人民医院消化内科, 广州 511300;3.中南大学湘雅三医院药学部, 长沙 410013

摘要:

近年来，对碳青霉烯类抗菌药物耐药的肠杆科细菌日益增多，临床治疗药物品种有限，死亡率较高。体外实验表明，碳青霉烯酶对厄他培南的亲和力显著高于碳青霉烯类其他品种，从而可消耗碳青霉烯酶，防止与之联用的碳青霉烯其他品种分解。因此，临床有厄他培南联合碳青霉烯类其他品种治疗耐碳青霉烯类肠杆科细菌。本文综述双碳青霉烯联合使用方案的机制、临床疗效及影响因素等，为临床治疗耐碳青霉烯类肠杆科细菌提供借鉴和指导。

关键词: 双碳青霉烯耐碳青霉烯肠杆科细菌作用机制临床疗效研究进展

DOI：10.13748/j.cnki.issn1007-7693.2020.20.022

分类号:R969

基金项目:

Advances in the Treatment of Carbapenem-resistant Enterobacteria by the Double Carbapenem Regimen

YE Chao¹, WANG Zhaohui¹, HU Ying¹, SONG Luping¹, ZHOU Wei¹, LIAO Linglong², WANG Chunjiang³

1.Department of Pharmacy, Ningxiang People's Hospital Affiliated to Hunan University of Chinese Medicine, Changsha 410600, China;2.Department of Gastroenterology, Zengcheng District People's Hospital of Guangzhou, Guangzhou 511300, China;3.Department of Pharmacy, The Third Xiangya Hospital of Central South University, Changsha 410013, China

Abstract:

In recent years, carbapenem-resistant Enterobacteria have been increasing, and the variety of clinical treatment drugs is limited, and the mortality rate is high. In vitro experiments have shown that carbapenemase has a significantly higher affinity for ertapenem than other carbapenem varieties, so it can consume carbapenemase and prevent the decomposition of other carbapenem varieties. Therefore, ertapenem is combined with other carbapenems to treat carbapenem-resistant Enterobacteria. This article reviews the mechanism, clinical efficacy and influencing factors of the double carbapene regimen, and provides reference and guidance for the clinical treatment of carbapenem-resistant Enterobacteria.

Key words: double carbapenem carbapenem-resistant Enterobacteria mechanism of action clinical efficacy research progress